Gynecological Devices Market Analysis, Size, Trends - United States - 2023-2029 - MedSuite - Includes: Gynecological Endoscope Devices, Endometrial Ablation Devices, Morcellator Device Market and 7 more.

Gynecological Devices Market Analysis, Size, Trends - United States - 2023-2029 - MedSuite - Includes: Gynecological Endoscope Devices, Endometrial Ablation Devices, Morcellator Device Market and 7 more.

In 2022, the gynecological devices market in the United States reached a value of approximately $1.3 billion, driven by nearly 3 million gynecological procedures performed annually. Our extensive research in the medical device market encompassed over 70 gynecological device companies across the United States. Through our comprehensive methodology, we analyzed market sizes, unit sales, company market shares, and developed accurate forecasts.

The complete report suite on the U.S. market for gynecological devices covers a wide range of products, including assisted reproduction technology devices, global endometrial ablation, uterine fibroid embolization devices, gynecological endoscopes, gynecological resection electrodes, morcellators, pelvic floor electrical stimulation devices, fluid management devices, pelvic organ prolapse repair devices, and hysterosalpingography (HSG) catheters.

DATA TYPES INCLUDED

Unit Sales, Average Selling Prices, Market Value & Growth Trends
Gynecological Procedure Volumes
Forecasts Until 2029, and Historical Data to 2019
Market Drivers & Limiters for Each Gynecological Device market
Competitive Analysis with Market Shares for Each Segment
Recent Mergers & Acquisitions
Disease Overviews and Demographic Information
Company Profiles, Product Portfolios and SWOT for Top Competitors

U.S. GYNECOLOGICAL DEVICES MARKET INSIGHTS

As companies vie for market share, pricing strategies in the gynecological devices industry become crucial. This has led to a downward trend in average selling prices (ASPs) across market segments. Lower prices may entice purchasers to explore alternative solutions, prompting providers of alternative gynecological devices to further reduce their prices in a cross-category price competition. The formation of purchasing groups by clinics has bolstered buyers' leverage, compelling sellers to offer competitive prices to secure broader market access. The competitive landscape puts pressure on sellers to ensure their pricing aligns with buyer expectations and demands.

One significant trend in the U.S. market for gynecological devices is the avoidance, when possible, of hysterectomies as a treatment option. Fibroids and endometriosis affect a significant proportion of women in the United States, with 20-25% of reproductive-age women and 11% of women between 15 and 44 being affected, according to the U.S. National Institutes of Health (NIH). To address these conditions, physicians are increasingly turning to minimally invasive treatments such as hysteroscopic surgeries, uterine artery embolization, and endometrial ablation, when the condition permits. These alternative procedures offer less invasiveness, shorter recovery periods, and have become preferred options for patients seeking to avoid the need for hysterectomy.

U.S. GYNECOLOGICAL DEVICES MARKET SHARE INSIGHTS

Hologic, Medtronic, Cooper Surgical, and Minerva Surgical emerged as the dominant players in the U.S. gynecological device market, collectively capturing more than 50% of the total market share.

Hologic dominated the U.S. gynecological device market with its strong presence in various segments, including global endometrial ablation, hysteroscopic morcellators, endoscopes, and fluid management devices.

Medtronic secured the second position, competing in the morcellator and fluid management device markets. Their TruClear™ Hysteroscopic morcellator contributed significantly to their market share in the morcellator device segment.

Minerva Surgical held the fourth position, participating in the global endometrial ablation, gynecological endoscope, morcellator, and fluid management markets. Their acquisition of the intrauterine portfolio from Boston Scientific in 2020 further strengthened their position.

Cooper Surgical emerged as the leading competitor in the assisted reproduction technology device, gynecological endoscope, and HSG catheter segments, contributing to their third-leading market share in the U.S. gynecological device market.

SEGMENTS COVERED

Assisted reproduction technology devices
Global endometrial ablation
Uterine fibroid embolization devices
Gynecological endoscopes
Gynecological resection electrodes
Morcellator devices
Pelvic floor electrical stimulation devices
Fluid management devices
Pelvic organ prolapse repair devices
Hysterosalpingography (HSG) catheters